DUBLIN, Ohio -- Cardinal Health, Inc., a leading provider of products and services supporting the healthcare industry, announces it has signed a five-year agreement with Novation, the healthcare contracting services company of VHA, Inc. and the University HealthSystem Consortium (UHC) to distribute medical and surgical products. The new contract extends a long-term relationship between Novation and Cardinal Health.
Under terms of the multi-source agreement, Cardinal Health will provide medical and surgical products and logistics services to Novation members including stockless and just-in-time delivery programs, customized pallet design, and patient labels and bar-coding services. The contract is effective Sept. 1, 2006 and runs through August 2011.
VHA's and UHC's 2,500 members will have access to Cardinal Health's full offering of medical and surgical products including kits, packs and trays; sutures, woven and nonwoven goods; needles and syringes; respiratory devices and skin care products. Cardinal Health will support Novation's supply standardization programs and participate in periodic reviews of products and pricing with Novation.
"This is a vote of confidence in our company and the value of our products and services for healthcare facilities nationwide," said Jim Neubauer, Cardinal Health's vice president of health systems. "We are pleased to continue building on our long-term relationship with such a valuable customer."
Source: Cardinal Health, Inc.
Health at Risk: The Impact of Antimicrobial Resistance From a Global to Local Health Perspective
March 6th 2024Discover the critical role infection preventionists play in combating multidrug-resistant organisms, from the impact on patient care to the challenges of treatment, and the evolving landscape of antimicrobial resistance with Katharine J Hoffman, MPH, CIC.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
FDA Approves Enmetazobactam for Complicated UTIs: A Breakthrough in Antimicrobial Therapy
February 26th 2024Enmetazobactam (Exblifep; Orchid Pharma) has received FDA approval for treating complicated urinary tract infections (cUTIs), offering a promising solution in the battle against antimicrobial resistance.